Since renal function in newborns is immature, the pharmacokinetics of drugs administered to neonates vary significantly from adult patients. The establishment of drug transport systems is a key process in the functional maturation of the nephron.
INTRODUCTION
At birth the fetus transitions from an aqueous environment in utero to a terrestrial environment. The physiological changes that are initiated at birth affect all organ systems to accommodate the rapidly shifting environment. A key issue has to do with developmental changes in drug and toxin transporters in the kidney and other organs that function at epithelial interfaces between the newborn and the outside world.
Transporters involved in the maintenance of homeostatic balance within this new environment must be adequately expressed and functionally regulated so that rapid environmental shifts and changes can be accommodated or recovered from safely (Wu et al., 2011) .
The kidneys play a particularly critical role in the elimination of toxins and drugs which may be encountered by or administered to the newborn. For example, various transporters including the ABC (ATP-binding cassette) and SLC (Solute carrier) families of transporters, together, are responsible for the transport of a majority of the drugs handled by the kidney. In particular, the transporters of SLC22 subfamily mediate the secretion of both endogenous and exogenous organic anions including a number of xenobiotics and pharmacological drugs. Endogenous and exogenous organic anions, including β -lactam antibiotics, HIV antiviral drugs, and diuretics, are excreted from the kidney by glomerular filtration as well as by secretion across the proximal tubule via these transporters (Miyazaki et al., 2004; Nigam et al., 2007) . The gene products of both Slc22a6 (OAT1) and Slc22a8 (OAT3) are localized to the basolateral membrane of 
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5 the proximal tubule (Kojima et al., 2002) and contribute to the secretion of a number of therapeutic agents and endogenous organic anions (Burckhardt and Burckhardt, 2003; Eraly et al., 2006; Vallon et al., 2008) .
It is known that the newborn kidney has a lower glomerular filtration rate compared to the adult and that the concentration of urine and secretion of organic compounds is reduced (Hook and Bailie, 1979) , and that renal expression of Oats increases substantially in postnatal rats and mice (Buist et al., 2002; Buist and Klaassen, 2004) .
Neonatal pharmacokinetics differ from adult parameters due to this functional renal immaturity, and it cannot be assumed that drug treatment of a newborn or premature infant can be extrapolated from the kinetics or therapeutic efficacy observed in adult patients (Warner, 1986) . In addition, the immature nature of the drug transport system at birth not only makes the kidney itself prone to toxic injury (Sekine and Endou, 2009 ), but also leaves other organ systems vulnerable to toxicants when the pharmacological agent has lower clearance rates. Although toxic injury due to the misdosing of drugs is a concern regardless of age, based on the immaturity of drug transport mechanisms, newborns can be particularly susceptible to overdosing from prescription errors (Chappell and Newman, 2004) .
In light of this, pharmacokinetic and dynamic studies specifically targeting the newborn are of critical importance for effective therapeutic treatment of this vulnerable population. However, little is known about the temporal expression of the main drug This article has not been copyedited and formatted. The final version may differ from this version. 
6 transporters throughout kidney development into adulthood. Using microarray analysis we carried out a comprehensive analysis of the profile of expression of SLC, ABC and SLC22 transporter families in the rodent kidney from early embryonic timepoints, through newborn stages and into maturity. Given the importance of OAT1 and OAT3 function in the elimination of a number of clinically important drugs we also performed a pharmacokinetic analysis using the prototypic substrate p-aminohippurate (PAH) during the neonatal period to gain insight into the functional state and maturation of the renal drug transport system. This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS
Microarray Analysis. Microarray analysis was carried out using Genespring GX 11 software. The whole embryonic rat kidney time course data was obtained from previously published datasets (Tsigelny et al., 2008) , and the mouse datasets from GUDMAP were downloaded at www.gudmap.org. All microarray datasets were processed using RMA (robust multi-array analysis) normalization. H-inulin (20 µg/kg) to the injection solution to also determine inulin clearance as previously described (Vallon et al., 2009 
RESULTS

Expression of SLC and ABC transporters in the embryonic, neonatal and mature kidney
The SLC and ABC transporter families comprise the two large families of drug transporters in the genome (He et al., 2009; Vasiliou et al., 2009; Wu et al., 2009 ). We sought to determine the expression profile of a comprehensive set of these transporters utilizing microarray expression data from rodent (rat) kidneys. Previously published data profiling the whole kidney transcriptome from its initial formation at e13 through each consecutive day of embryonic development (e14-e22) as well as time points
profiling the kidney at birth (P0), week 1, week 4 and adulthood was obtained (Tsigelny et al., 2008) . A stage model as described in Tsigelny (Giacomini et al., 2010) . Accordingly, we determined the expression profiles of these clinically important transporters during kidney development ( Figure 3A ; Supplemental Table 4 ). Of the 22 probe sets examined for these transporters, 11 showed a 2-fold increase in at least one consecutive stage comparison ( Figure 3B ). By comparing the expression profiles between temporally sequential stages, it is evident that for the majority of these transporters the greatest fold change in expression occurs between the transition between birth to maturity (the comparison between the postnatal stage and the mature stage).
This article has not been copyedited and formatted. The final version may differ from this version. Although it is clear that the largest increase in "pharmaceutically" relevant transporters also seems to occur between birth to maturity in the kidney, it was also important to determine whether the localization of these transporters was specific to a developing nephron segment of the embryonic kidney. The embryonic kidney comprises a number of developing nephron and collecting duct segments such as the ureteric bud, proximal implies that the drug transport function may be partially established even in the e15.5
proximal tubule and that drug transporters already show distinct segmental localization along the nephron even at this relatively early time point during kidney development.
These transporters may be functional even at this time (Rosines et al., 2007; Sweet et al., 2006) .
Investigating the functional maturation of OAT1 and OAT3 in the postnatal kidney using PAH as a representative organic anion for in vivo physiological studies.
Both Oat1 and Oat3 are upregulated in the maturing kidney and are specifically upregulated in the developing proximal tubule. These transporters mediate the basolateral uptake of a plethora of drugs including NSAIDS, antivirals, beta-lactams and methotrexate (Miyazaki et al., 2004; Nagle et al.; Nigam et al., 2007; Sekine et al., 2000; VanWert et al., 2007) . Our previous studies in adult knockout mice for these two genes revealed that OAT1 but not OAT3 mediates the proximal tubular secretion of the prototypic organic anion p-aminohippurate and endogenous organic anions (Eraly et al., 2006; Vallon et al., 2008) . OAT1 and OAT3 are also essential for diuretic delivery into the lumen of the proximal tubule (Vallon et al., 2008) . Whereas some information is available on the OAT1 and OAT3 systems in adult rats, mice, and humans, very little is known about the newborn and juvenile situation, yet many of these drugs are also applied in the neonatal period.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 5C ). This suggests that, although organic anion transport is functional in the postnatal pups, its activity is immature and is dependent on the age of the neonate. The data seems generally consistent with the expression profiling described earlier.
The in vivo clearance of PAH by OAT1 and OAT3 in the postnatal kidney
Studies in knockout mice revealed that Oat1 is the principle transporter of PAH in the adult (Eraly et al., 2006; Vallon et al., 2008) . However it is unclear whether this is the case in the newborn, which is in a dynamic state, at least based on the expression data presented here. This is an important issue since newborns and juveniles may be dosed with organic anion drugs based upon extrapolations from adult studies. at 2 weeks of age ( Figure 6 ). Body weight and the volume of distribution for PAH and inulin were similar between WT and Oat1 -/-and Oat3 -/-mice ( Figure 6A and 6B).
Whereas the clearance of inulin was comparable between genotypes, the clearance of PAH and the difference between PAH and inulin clearance (as an indirect measure of renal PAH secretion) were significantly lower in Oat1 -/-than in WT mice ( Figure 6B and C). Figure 6B presents 
DISCUSSION
The kidney is comprised of a number of epithelial cell types which carry out various essential roles including metabolite excretion, electrolyte homeostatic maintenance and drug and toxin transport. Although pharmacokinetic studies often focus on the fate of drugs in the adult situation, there is a critical need to understand the kinetics of pharmacological agents in newborns and infants given that their renal functional capacity is still undergoing maturation (Hook and Bailie, 1979) . Using previously published rat and mouse mRNA microarray expression data we describe the expression of many components of the major drug transport systems during kidney development, through the postnatal period and on to adulthood. Overall, there appears to be an upregulation of the SLC and ABC transporters with developmental time. The expression of SLC22 family of transporters also increases with time, but perhaps of particular interest are the clinically relevant transporters, of which 11 transporters are upregulated at least 2-fold across the development stages analyzed.
The specific expression of a large proportion of these clinically relevant transporters (Slc47a1, Slc22a2, Slc15a2, Slc22a1, Slc22a6 and Slc22a8) in the e15.5 developing proximal tubule suggests that drug transport systems are present early in renal development. In fact, it has been shown previously using whole embryonic kidney culture in vitro that OAT1 mediated uptake of the fluorescent specific substrate
This article has not been copyedited and formatted. The final version may differ from this version. fluorescein can be observed after a week of culture of an e13 rat kidney, a time at which proximal tubule formation should be well underway (Sweet et al., 2006) .
The expression of Oats in postnatal development has been measured in mice and rats previously (Buist et al., 2002; Buist and Klaassen, 2004 ) and shown to increase to mature levels in the weeks following birth. Oat1 and Oat3 proteins localize to proximal tubule (Hwang et al., 2010) , and increases in staining are visible until three weeks postnatally, when the tissue is similar in protein level to the adult organ but remains early enough in development that gender based differences are negligible. Although there exist some differences in the expression and or localization of Oat drug transporters along the nephron in different species (Enomoto et al., 2002; Kojima et al., 2002; Ljubojevic et al., 2004; Wu et al., 2009) , rodents provide an accessible model to carry out pharmacodynamic and kinetic studies. In light of these divergences, experimental studies using human tissues and cells would be ideally relevant for clinical benefit. However the study of the subtle differences between rodent and human may be key to understanding the vulnerabilities and susceptibilities to drug/metabolite toxicity that have evolved in humans. While previous analyses of expression and protein localization corroborate a dramatic increase in expression, there has yet to be a functional analysis of the transport systems to examine the crucial postnatal developmental phase.
The maturation of the organic anion transport systems in the postnatal mouse kidney was studied using the prototypic organic anion PAH. The kinetics of PAH reflect the kinetic behavior of any pharmacological agent transported by OAT1. Clearance of PAH increases nearly 4-fold between week 1 and week 3 in the mouse and, by using data from mature mice, it is clear that this increase continues from 3 weeks to adulthood.
Therefore, the drug transport system can be considered relatively immature even at 3 weeks of age in the mouse. The attenuation of PAH clearance in the Oat1 knockout animal confirms that PAH is indeed transported via OAT1 in the young kidney similar to the adult situation.
Although there were increases in both mRNA levels of clinical drug transporters and in PAH clearance in the kidney in the postnatal to mature period, it is still unclear what triggers these increases. Previous studies suggest that hormonal regulation may be responsible for the expression of the transporters. Studies have shown that gender differences in Oat 1 expression are influenced by the sex steroids testosterone and estradiol (Ljubojevic et al., 2004) . It is also known that the corticosteroid dexamethasone, increases PAH uptake in both rat and human renal slices (Fleck et al., 2002) . Thyroid hormones have also been implicated in the regulation of OAT activity in the postnatal kidney, using assessment of PAH clearance (Braunlich, 1984) . Given that there is a surge in the levels of catecholamine, glucocorticoids and thyroid hormones at birth (Blackburn, 2007; Challis et al., 2000; Freemark, 1999) , it is possible that circulating hormone levels are responsible for the maturational increases in the mRNA levels of the drug transporters. The impetus for upregulation in expression may also be This article has not been copyedited and formatted. The final version may differ from this version. linked to the feeding and fasting behavior that is newly established after birth, as may be occurring with regulation of liver transporters (Eder and Ringseis; Kok et al., 2003) .
The fold-change increase in expression and function could also be attributed to morphological changes that are occurring in the maturing kidney. In humans, nephrogenesis is complete by 34 weeks of gestation, while in the rat nephrogenesis is complete between P7-P10 (Dickinson et al., 2005) . Although the additional development of new nephrons could be responsible for the increases in transporter mRNA levels, it is more likely that the postnatal changes in segmental maturation of the individual S1, S2
and S3 segments of the proximal tubule could be a major contributing factor. In the rabbit, it is not until postnatal day 40 that all segments of the outer cortical tubules have reached maturity (Evan et al., 1983) . Over this period of time all segments of the proximal tubule show increases in length with the S1 segment undergoing a 6-fold increase in segment length (Evan et al., 1983) . In light of this, it should be considered pharmacological safety is to be enhanced and overdose or toxicity issues are to be avoided. Understanding how epithelial drug transporters, present at multiple interfaces (not only the blood-nephron barrier but also transepidermal, gut and blood-brain barrier), are regulated pre and postnatally is a key component to this endeavor, as well as understanding how intracellular drug metabolizing enzymes are working in concert with the transport mechanisms to detoxify or activate the pharmacological compounds.
To this end, this study should serve a basis for investigations into the pharmacokinetics of neonatally relevant drugs transported by the renal drug transport system in the future.
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